Skip to main content
92 results:
21. Biomarker Out-Licensing  
SphingoTec has established an extended intellectual property portfolio covering markers for acute care conditions such as sepsis, acute heart failure and acute kidney injury.  
22. Modal Box  
Diese Seite richtet sich ausschließlich an Beschäftigte im Gesundheitswesen. Wenn Sie fortfahren, bestätigen Sie, dass Sie im Gesundheitswesen tätig sind.  
23. Interdepartmental testing of the kidney function biomarker penKid in routine care at Heidelberg University Hospital and the Heidelberg Kidney Center  
Four units at the University Hospital Heidelberg and Heidelberg Kidney Center implement Proenkephalin (penKid) in a pilot biomarker-based treatment approach to diagnose AKI faster and monitor it more…  
24. Medical thought leaders in critical care aim to advance precision medicine using biomarker-based approaches  
International medical experts discussed the latest developments in diagnostic and therapeutic innovations for advancing precision medicine in critically ill patients during the 4th Scientific…  
25. Endothelial function biomarker bioactive Adrenomedullin (bio-ADM) enables triage of sepsis patients in the emergency department  
New findings support the clinical value of the biomarker bio-ADM for triaging sepsis patients in ED, exceeding the prognostic performance of routine biomarkers. So far, the predictive potential of…  
26. LinkedIn Test  
Follow our Journey on Social Media Learn more about The Biomarker Company  
27. Thank You  
Thank you for your request We will reach out to you shortly. SphingoTec GmbH Neuendorfstr. 15 16761 Hennigsdorf Phone: 03302 205650 Email: info[at]  
28. About Us  
SphingoTec develops and markets innovative in vitro diagnostic (IVD) tests for novel and proprietary blood-based protein biomarkers. These tests allow for the diagnosis, outcome prediction, and…  
29. Service Measurements  
Next to our Nexus IB10 automated and portable immunoassay system we also provide customized MTP assays and testing services to fulfill the specific requirements of our customers.  
30. SphingoTec appoints Jörg Menten as CEO to accelerate commercialization and global growth  
Jörg Menten, previously acting as Chief Commercial Officer of the company, will focus on successfully commercializing the biomarker-based diagnostics that address high unmet needs in critical care…  
Search results 21 until 30 of 92